Decibel Therapeutics, which focuses on therapies for hearing and balance disorders, has tapped 4G Clinical to provide randomization and trial supply management.
4G will, specifically, provide IxRS/RTSM support. Financial terms of the deal weren’t disclosed.
RTSM systems support the randomization of patients into different arms of a trial and the supply of study drugs to sites. The technology has evolved from the phone-based systems of the 1990s, known by the abbreviation IVRS, to the web-based platforms in use today.
“The complexity of today’s trials requires an RTSM solution that is flexible enough to adapt as trials evolve,” Heather Wolff, a senior director at Decibel, said in a statement. “4G Clinical’s modern technology is best-in-class and the tool that will be the best fit for an emerging biotech company such as Decibel.”
4G’s chief executive, David Kelleher, said in the announcement that as biotechs make critical advancements in science, the company will remain focused on making “it easier for them to let the science take the lead in their trials.”
Medidata and Paraxel are 4G’s main competition in the market.